Regeneron raises Eylea sales forecast, shares at record

(Reuters) - Regeneron Inc's blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts' expectation.